Cortrosyn

Iritis, Ophthalmia, Sympathetic, Pemphigus + 22 more

Treatment

43 FDA approvals

20 Active Studies for Cortrosyn

What is Cortrosyn

Tetracosactide

The Generic name of this drug

Treatment Summary

Tetracosactide (also known as Cosyntropin) is a synthetic hormone that is identical to a segment of the natural hormone adrenocorticotropic hormone (ACTH). This peptide works in the same way as natural ACTH, stimulating the production of corticosteroids in the adrenal cortex. Tetracosactide is absorbed over a longer period of time than natural ACTH, so treatment can be continued with less frequent doses.

Cortrosyn

is the brand name

image of different drug pills on a surface

Cortrosyn Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cortrosyn

Tetracosactide

2003

10

Approved as Treatment by the FDA

Tetracosactide, also known as Cortrosyn, is approved by the FDA for 43 uses which include Jaundice, Hemolytic and Dermatomyositis .

Jaundice, Hemolytic

Helps manage acquired hemolytic jaundice

Dermatomyositis

Helps manage Dermatomyositis (DM)

Nephrotic Syndrome

Helps manage Nephrotic Syndrome

Rheumatoid Arthritis

Helps manage Rheumatoid Arthritis

acquired hemolytic jaundice

Helps manage acquired hemolytic jaundice

Choroiditis

Helps manage Choroiditis

Ophthalmia, Sympathetic

Helps manage Ophthalmia, Sympathetic

Keratitis

Helps manage Keratitis

Ulcerative Colitis

Helps manage Ulcerative Colitis

Ankylosing Spondylitis (AS)

Helps manage Ankylosing Spondylitis (AS)

Still's Disease

Helps manage Still's Disease

Multiple sclerosis exacerbation

Helps manage Multiple sclerosis exacerbation

Bell's Palsy

Helps manage Bell's Palsy

Periarteritis nodosa

Helps manage Periarteritis nodosa

Choroiditis

Helps manage Choroiditis

Pink Eye

Helps manage Conjunctivitis

Adrenal Insufficiency

Pemphigus

Helps manage Pemphigus

exfoliative erythroderma

Helps manage exfoliative erythroderma

Dermatomyositis (DM)

Helps manage Dermatomyositis (DM)

Ankylosing Spondylitis

Helps manage Ankylosing Spondylitis (AS)

Ulcerative Colitis

Helps manage Ulcerative Colitis

Arthritis, Juvenile

Helps manage Still's Disease

Uveitis

Helps manage Uveitis

Iritis

Helps manage Iritis

Acute Gouty Arthritis

Panhypopituitarism

Helps manage Panhypopituitarism

Conjunctivitis

Helps manage Conjunctivitis

Optic Neuritis

Helps manage Optic Neuritis

Acute Rheumatic Fever

Helps manage Acute Rheumatic Fever

Bell Palsy

Helps manage Bell's Palsy

Adrenal gland hypofunction

Pemphigus

Helps manage Pemphigus

Uveitis

Helps manage Uveitis

Scleroderma

Helps manage Scleroderma

Hypopituitarism

Helps manage Panhypopituitarism

Rheumatic Fever

Helps manage Acute Rheumatic Fever

Multiple Sclerosis

Helps manage Multiple sclerosis exacerbation

Arthritis, Gouty

Lupus Erythematosus

Helps manage Lupus Erythematosus

Optic Neuritis

Helps manage Optic Neuritis

Psoriatic Arthritis

Helps manage Psoriatic Arthritis

Iritis

Helps manage Iritis

Effectiveness

How Cortrosyn Affects Patients

Cosyntropin is a synthetic form of ACTH (adrenocorticotropic hormone) that has similar effects to natural ACTH, with the potential to stimulate the adrenal cortex. The effects of Cosyntropin are maximized at 0.25 milligrams (mg) and are comparable to the effects of 25 units of natural ACTH. Cosyntropin is less likely to cause an allergic reaction than natural ACTH, as it lacks part of the amino acid sequence that is responsible for causing an immune response. In addition to stimulating the adrenal cortex, Cosyntropin may also increase melanin production and

How Cortrosyn works in the body

Cosyntropin connects to a receptor on the cells in the adrenal gland. This connection stimulates the production of hormones, like cortisol and aldosterone, from cholesterol. In people with healthy adrenal glands, cosyntropin increases the amount of hormones produced. However, it won't have much effect on those with adrenal insufficiency.

When to interrupt dosage

The endorsed portion of Cortrosyn is contingent upon the diagnosed condition, including Exfoliative dermatitis, Arthritis, Gouty and Uveitis. The dosage fluctuates based on the method of administration (e.g. Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral or Injection, solution) as seen in the table below.

Condition

Dosage

Administration

Ophthalmia, Sympathetic

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Pemphigus

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Uveitis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Pink Eye

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Jaundice, Hemolytic

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Periarteritis nodosa

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Hypopituitarism

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Multiple Sclerosis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

exfoliative erythroderma

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Arthritis, Gouty

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Dermatomyositis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Optic Neuritis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Adrenal Insufficiency

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Ulcerative Colitis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Rheumatoid Arthritis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Bell Palsy

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Ankylosing Spondylitis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Rheumatic Fever

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Arthritis, Juvenile

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Iritis

, 0.25 mg/mL, 0.25 mg, 1.0 mg/mL

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intramuscular, Suspension - Intramuscular, Suspension, Intramuscular; Intravenous; Parenteral, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous; Parenteral, Injection, solution, Injection, solution - Intravenous

Warnings

Cortrosyn has twelve contraindications and should not be employed when experiencing any of the conditions appearing in the following table.

Cortrosyn Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Hypersensitivity

Do Not Combine

Mycoses

Do Not Combine

Virus Diseases

Do Not Combine

Cushing Syndrome

Do Not Combine

Adrenogenital Syndrome

Do Not Combine

Congestive heart failure

Do Not Combine

Peptic Ulcer

Do Not Combine

Addison Disease

Do Not Combine

Psychotic Disorders

Do Not Combine

Pulse Frequency

Do Not Combine

Bacterial Infections

Do Not Combine

There are 20 known major drug interactions with Cortrosyn.

Common Cortrosyn Drug Interactions

Drug Name

Risk Level

Description

Valproic acid

Major

Tetracosactide may increase the hepatotoxic activities of Valproic acid.

7-Nitroindazole

Moderate

The risk or severity of liver damage can be increased when Tetracosactide is combined with 7-Nitroindazole.

Acetazolamide

Moderate

The risk or severity of liver damage can be increased when Tetracosactide is combined with Acetazolamide.

Amobarbital

Moderate

The risk or severity of liver damage can be increased when Tetracosactide is combined with Amobarbital.

Barbexaclone

Moderate

The risk or severity of liver damage can be increased when Tetracosactide is combined with Barbexaclone.

image of a doctor in a lab doing drug, clinical research

Cortrosyn Novel Uses: Which Conditions Have a Clinical Trial Featuring Cortrosyn?

222 active trials are currently being conducted to determine the potential of Cortrosyn in alleviating symptoms of Choroiditis, Multiple Sclerosis and Sympathetic Ophthalmia.

Condition

Clinical Trials

Trial Phases

Pink Eye

0 Actively Recruiting

Dermatomyositis

0 Actively Recruiting

Rheumatoid Arthritis

54 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Ophthalmia, Sympathetic

0 Actively Recruiting

Pemphigus

0 Actively Recruiting

Bell Palsy

0 Actively Recruiting

Multiple Sclerosis

0 Actively Recruiting

exfoliative erythroderma

0 Actively Recruiting

Lupus Erythematosus

3 Actively Recruiting

Phase 4, Phase 1, Not Applicable

Nephrotic Syndrome

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Psoriatic Arthritis

29 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Phase 4, Phase 2

Uveitis

3 Actively Recruiting

Not Applicable, Phase 3

Ankylosing Spondylitis

3 Actively Recruiting

Phase 3, Not Applicable

Scleroderma

10 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1

Arthritis, Gouty

0 Actively Recruiting

Ulcerative Colitis

14 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1

Rheumatic Fever

0 Actively Recruiting

Periarteritis nodosa

0 Actively Recruiting

Jaundice, Hemolytic

0 Actively Recruiting

Choroiditis

0 Actively Recruiting

Cortrosyn Reviews: What are patients saying about Cortrosyn?

3

Patient Review

8/25/2012

Cortrosyn for Problem with Adrenal Gland

The injection was quite painful and it left a really unpleasant taste in my mouth.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cortrosyn

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is Cortrosyn given?

"Cortrosyn can be administered in different ways depending on what it is being used for. It can be given as an intramuscular injection or as a direct intravenous injection for a quick test of adrenal function. It can also be given as an intravenous infusion over a period of 4 to 8 hours to provide a greater stimulus to the adrenal glands."

Answered by AI

What does Cortrosyn treat?

"Cortrosyn is a man-made version of a natural substance made by the body called ACTH. It is used to diagnose problems with the adrenal gland, such as Addison's disease or insufficiency caused by corticosteroid use. Cortrosyn is available in generic form."

Answered by AI

What kind of drug is Cortrosyn?

"Cortrosyn is a prescription medicine used as a diagnostic tool for adrenocortical insufficiency. Cortrosyn may be used alone or with other medications. Cortrosyn belongs to a class of drugs called diagnostic tools, specifically for endocrine conditions."

Answered by AI

What is cosyntropin used for?

"Cosyntropin is a man-made copy of a hormone that is used to test patients for adrenal gland problems. This testing is the best way to diagnose adrenal gland problems."

Answered by AI

Clinical Trials for Cortrosyn

Image of McMaster Children's Hospital - Digestive Diseases Clinic in Hamilton, Canada.

Vancomycin for Ulcerative Colitis

18+
All Sexes
Hamilton, Canada

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Phase 2
Waitlist Available

McMaster Children's Hospital - Digestive Diseases Clinic

Neeraj Narula, MD

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Cortrosyn clinical trials?

We made a collection of clinical trials featuring Cortrosyn, we think they might fit your search criteria.
Go to Trials

Have you considered Cortrosyn clinical trials?

We made a collection of clinical trials featuring Cortrosyn, we think they might fit your search criteria.
Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention

Recruiting
Has No Placebo

Weill Cornell Medical College

Iris Y Navarro-Millán, MD

Bristol-Myers Squibb

Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Waitlist Available
Has No Placebo

Humana Healthcare Research, Inc. (+1 Sites)

Have you considered Cortrosyn clinical trials?

We made a collection of clinical trials featuring Cortrosyn, we think they might fit your search criteria.
Go to Trials